Skip to content

Clinical trials

Malaria, Falciparum trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Malaria, Falciparum Clear all

450 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20014
20028
20037
200414
200521
200627
200717
200814
200917
201018
201115
201215
201319
201424
201514
201613
201718
201814
201916
202018
202124
202219
202326
202420
202519
202617

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed335
Unknown status30
Terminated24
Recruiting20
Not yet recruiting14
Active, not recruiting12
Withdrawn12
Suspended3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Oxford53
National Institute of Allergy and Infectious Diseases (NIAID)38
Sanaria Inc.29
GlaxoSmithKline21
London School of Hygiene and Tropical Medicine21
Medicines for Malaria Venture20
Radboud University Medical Center20
U.S. Army Medical Research and Development Command14
Centers for Disease Control and Prevention13
Novartis Pharmaceuticals10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Malaria, Falciparum450
Malaria268
Malaria, Vivax30
Anemia12
Parasitic Diseases12
Protozoan Infections9
Infections5
Disease4
HIV Infections4
Parasitemia4

Trials

Showing 26 to 50 of 450. Each trial links to its page on Pharma Observatory.

350 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.